SCD and cancer: In addition, Mayo Clinic Comprehensive Cancer Center Research has developed a novel small molecule inhibitor MTI-301 blocking the activity of SCD1, which promotes fatty acid synthesis in cancer cells (Project number: 4R44CA272064-02).